Pulse Biosciences Executives Buy Over $13M in Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 55 minutes ago
0mins
Should l Buy PLSE?
Source: seekingalpha
- Executive Stock Purchases: Pulse Biosciences' CEO Paul LaViolette and co-chairman Robert Duggan purchased over $13 million in company stock on Monday through the company's at-the-market equity offering program, indicating strong confidence in the company's future.
- Duggan's Acquisition Details: Duggan acquired approximately 660,200 shares at $19.69 each, increasing his ownership by about 1% to approximately 48.2 million shares, reflecting his recognition of the company's long-term value.
- LaViolette's Acquisition Details: LaViolette also added 15,000 shares on the same day for nearly $295,400, further solidifying his stake in the company and demonstrating a positive outlook on its prospects.
- Market Reaction: Following this news, Pulse Biosciences' stock rose approximately 7% in premarket trading, indicating a positive investor response to the executives' purchases, which may enhance market confidence in the company's stock.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PLSE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PLSE
Wall Street analysts forecast PLSE stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 19.080
Low
22.00
Averages
22.00
High
22.00
Current: 19.080
Low
22.00
Averages
22.00
High
22.00
About PLSE
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. It is pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation (AF) and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Its nsPFA Percutaneous Electrode System consists of a disposable, percutaneous, needle electrode for use with its CellFX Console. Its surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment of AF. The CellFX Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. It is also developing a Nanosecond PFA 360-degree Cardiac Catheter System.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pulse Biosciences Executives Buy Over $13M in Stock
- Executive Stock Purchases: Pulse Biosciences' CEO Paul LaViolette and co-chairman Robert Duggan purchased over $13 million in company stock on Monday through the company's at-the-market equity offering program, indicating strong confidence in the company's future.
- Duggan's Acquisition Details: Duggan acquired approximately 660,200 shares at $19.69 each, increasing his ownership by about 1% to approximately 48.2 million shares, reflecting his recognition of the company's long-term value.
- LaViolette's Acquisition Details: LaViolette also added 15,000 shares on the same day for nearly $295,400, further solidifying his stake in the company and demonstrating a positive outlook on its prospects.
- Market Reaction: Following this news, Pulse Biosciences' stock rose approximately 7% in premarket trading, indicating a positive investor response to the executives' purchases, which may enhance market confidence in the company's stock.
See More
Pulse Biosciences to Participate in BofA Healthcare Conference
- Conference Participation: Pulse Biosciences (NASDAQ:PLSE) announced its participation in the 2026 BofA Securities Healthcare Conference, with management scheduled to present on May 13 at 4:35 PM PT, showcasing innovations in bioelectric medicine.
- Technology Overview: The company's nPulse™ technology employs nanosecond pulsed field ablation (nsPFA™) energy to non-thermally clear cells while sparing adjacent non-cellular tissue, indicating potential applications in atrial fibrillation and other critical areas.
- Webcast Availability: The presentation will be available via live and recorded webcast on the company's investor website under the
See More
Turbett Surgical Appoints New CEO Kevin Danahy
- Leadership Change: Turbett Surgical has appointed Kevin Danahy as the new CEO, known for his 'founder mentality,' with a mandate to transform the company culture towards high performance, thereby enhancing its capabilities in clinical expansion and commercial excellence.
- Extensive Industry Experience: Danahy previously held key executive roles at Pulse Biosciences, successfully guiding the company through a transition to focus on cardiac and oncology, and at Solmetex, where he rebuilt the executive team and achieved a successful exit, showcasing his deep background in the medical device industry.
- Clear Strategic Goals: Danahy emphasizes cultivating a success-driven environment to enhance team cohesion, aiming to exceed growth expectations and improve service delivery for surgeons, nursing staff, and hospital professionals, indicating a clear vision for the company's future development.
- Technological Innovation and Market Expansion: Turbett Surgical focuses on manufacturing mobile sterilization pods and consumable filters to enhance surgical equipment sterilization efficiency, and Danahy's addition is expected to accelerate the company's expansion in the US and international markets, further solidifying its competitive position in the medical device sector.
See More
Pulse Biosciences (PLSE) Q1 2025 Earnings Transcript
See More
Pulse Biosciences Q1 Earnings Beat Expectations
- Earnings Highlights: Pulse Biosciences reported a Q1 GAAP EPS of -$0.27, beating expectations by $0.05, indicating a slight improvement in financial performance despite remaining in the red.
- Revenue Performance: The company achieved revenue of $0.4 million, in line with market expectations, suggesting stable sales in the current market environment, which may lay the groundwork for future growth.
- Technological Advancements: Pulse Biosciences is accelerating the development of its Pulse Cardiac Catheter Ablation System, aiming to enhance its competitive position in cardiac treatment, although the current risk-reward profile remains weak.
- Shareholder Reaction: Despite exceeding Q4 earnings expectations, Pulse Biosciences' stock price slipped, reflecting market concerns over its share sale transaction, which could impact investor confidence.
See More
Pulse Biosciences Reports Positive Clinical Data for Cardiac Catheter System
- Clinical Data Highlights: Pulse Biosciences presented positive clinical data for its nPulse Cardiac Catheter System at the Heart Rhythm meeting, showing a 100% procedural success rate at 6 months among 95 patients, indicating high efficiency and durability of the technology.
- Significant Long-term Outcomes: At the 12-month follow-up, 96% of 53 patients achieved procedural success, with a 90% freedom rate from atrial fibrillation, underscoring the potential and reliability of this technology in treating atrial fibrillation.
- Enhanced Procedural Efficiency: The average procedure time was 60.2 minutes with an 18.6-minute left atrial dwell time, demonstrating consistency and efficiency across multiple investigator sites, which could redefine treatment standards for atrial fibrillation ablation.
- Good Safety Profile: Among 177 patients, only 1.7% experienced serious adverse events related to the primary safety endpoint, indicating the clinical safety of the technology and enhancing its competitive position in the market.
See More
Pulse Biosciences Executives Buy Over $13M in Stock
- Executive Stock Purchases: Pulse Biosciences' CEO Paul LaViolette and co-chairman Robert Duggan purchased over $13 million in company stock on Monday through the company's at-the-market equity offering program, indicating strong confidence in the company's future.
- Duggan's Acquisition Details: Duggan acquired approximately 660,200 shares at $19.69 each, increasing his ownership by about 1% to approximately 48.2 million shares, reflecting his recognition of the company's long-term value.
- LaViolette's Acquisition Details: LaViolette also added 15,000 shares on the same day for nearly $295,400, further solidifying his stake in the company and demonstrating a positive outlook on its prospects.
- Market Reaction: Following this news, Pulse Biosciences' stock rose approximately 7% in premarket trading, indicating a positive investor response to the executives' purchases, which may enhance market confidence in the company's stock.
See More
Pulse Biosciences to Participate in BofA Healthcare Conference
- Conference Participation: Pulse Biosciences (NASDAQ:PLSE) announced its participation in the 2026 BofA Securities Healthcare Conference, with management scheduled to present on May 13 at 4:35 PM PT, showcasing innovations in bioelectric medicine.
- Technology Overview: The company's nPulse™ technology employs nanosecond pulsed field ablation (nsPFA™) energy to non-thermally clear cells while sparing adjacent non-cellular tissue, indicating potential applications in atrial fibrillation and other critical areas.
- Webcast Availability: The presentation will be available via live and recorded webcast on the company's investor website under the
See More
Turbett Surgical Appoints New CEO Kevin Danahy
- Leadership Change: Turbett Surgical has appointed Kevin Danahy as the new CEO, known for his 'founder mentality,' with a mandate to transform the company culture towards high performance, thereby enhancing its capabilities in clinical expansion and commercial excellence.
- Extensive Industry Experience: Danahy previously held key executive roles at Pulse Biosciences, successfully guiding the company through a transition to focus on cardiac and oncology, and at Solmetex, where he rebuilt the executive team and achieved a successful exit, showcasing his deep background in the medical device industry.
- Clear Strategic Goals: Danahy emphasizes cultivating a success-driven environment to enhance team cohesion, aiming to exceed growth expectations and improve service delivery for surgeons, nursing staff, and hospital professionals, indicating a clear vision for the company's future development.
- Technological Innovation and Market Expansion: Turbett Surgical focuses on manufacturing mobile sterilization pods and consumable filters to enhance surgical equipment sterilization efficiency, and Danahy's addition is expected to accelerate the company's expansion in the US and international markets, further solidifying its competitive position in the medical device sector.
See More
Pulse Biosciences (PLSE) Q1 2025 Earnings Transcript
See More
Pulse Biosciences Q1 Earnings Beat Expectations
- Earnings Highlights: Pulse Biosciences reported a Q1 GAAP EPS of -$0.27, beating expectations by $0.05, indicating a slight improvement in financial performance despite remaining in the red.
- Revenue Performance: The company achieved revenue of $0.4 million, in line with market expectations, suggesting stable sales in the current market environment, which may lay the groundwork for future growth.
- Technological Advancements: Pulse Biosciences is accelerating the development of its Pulse Cardiac Catheter Ablation System, aiming to enhance its competitive position in cardiac treatment, although the current risk-reward profile remains weak.
- Shareholder Reaction: Despite exceeding Q4 earnings expectations, Pulse Biosciences' stock price slipped, reflecting market concerns over its share sale transaction, which could impact investor confidence.
See More
Pulse Biosciences Reports Positive Clinical Data for Cardiac Catheter System
- Clinical Data Highlights: Pulse Biosciences presented positive clinical data for its nPulse Cardiac Catheter System at the Heart Rhythm meeting, showing a 100% procedural success rate at 6 months among 95 patients, indicating high efficiency and durability of the technology.
- Significant Long-term Outcomes: At the 12-month follow-up, 96% of 53 patients achieved procedural success, with a 90% freedom rate from atrial fibrillation, underscoring the potential and reliability of this technology in treating atrial fibrillation.
- Enhanced Procedural Efficiency: The average procedure time was 60.2 minutes with an 18.6-minute left atrial dwell time, demonstrating consistency and efficiency across multiple investigator sites, which could redefine treatment standards for atrial fibrillation ablation.
- Good Safety Profile: Among 177 patients, only 1.7% experienced serious adverse events related to the primary safety endpoint, indicating the clinical safety of the technology and enhancing its competitive position in the market.
See More
